# Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

> **NCT05897190** · PHASE1 · COMPLETED · sponsor: **Argorna Pharmaceuticals Co., LTD** · enrollment: 60 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 mRNA vaccine (RBMRNA-405)
- **BIOLOGICAL:** CoronaVac®

## Key facts

- **NCT ID:** NCT05897190
- **Lead sponsor:** Argorna Pharmaceuticals Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2022-06-13
- **Final completion:** 2023-05-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05897190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05897190, "Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05897190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*